Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 11/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CDK2AP1 | O14519 | 5/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5554768 | 0.91 | CHEK1 (0.51) | CHEK1CDK2AP1 | |
| SCHEMBL5001102 | 0.91 | USP30 (0.43) | CHEK1KDM4EPOLBCDK2AP1CNR1 | |
| SCHEMBL4703508 | 0.90 | KDM4E (0.46) | CHEK1KDM4EPOLBCDK2AP1CNR1 | |
| SCHEMBL5556375 | 0.89 | CHEK1 (0.54) | CHEK1CDK2AP1 | |
| SCHEMBL4702699 | 0.86 | CHEK1 (0.54) | CHEK1KDM4ECDK2AP1RAB9ACHRNB2 | |
| SCHEMBL4209769 | 0.84 | CHEK1 (0.55) | CHEK1CDK2AP1 | |
| SCHEMBL5784504 | 0.84 | CHEK1 (0.55) | CHEK1CDK2AP1 | |
| SCHEMBL1563863 | 0.84 | USP30 (0.53) | CHEK1CDK2AP1 | |
| SCHEMBL5001107 | 0.84 | KDM4E (0.40) | CHEK1KDM4EPOLBCDK2AP1 | |
| Hydrochloric Acid SCHEMBL4221917 | 0.84 | CHEK1 (0.55) | CHEK1CDK2AP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1660474-B1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | TPMT, ABCG2, TYMP | CHEK1 297/4885KDM4E 1951/4885POLB 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.